Introduction:
The global pneumococcal vaccine market is experiencing significant growth, driven by increasing awareness about the importance of vaccination in preventing pneumococcal diseases. According to recent data, the global pneumococcal vaccine market is expected to reach $9.3 billion by 2026, with a CAGR of 5.8%. In India, the demand for pneumococcal vaccines is also on the rise, with a growing emphasis on immunization programs to combat infectious diseases.
Explore Top 20 Leading Pneumococcal Vaccine Brands in India 2026:
1. Pneumovax 23 by Pfizer
Pneumovax 23 is a leading pneumococcal vaccine brand in India, known for its high efficacy in preventing pneumococcal diseases. With a market share of 25%, Pfizer continues to dominate the pneumococcal vaccine market in India.
2. Prevnar 13 by Pfizer
Prevnar 13 is another popular pneumococcal vaccine brand in India, capturing a market share of 20%. Pfizer’s innovative vaccine formulation has been instrumental in reducing the incidence of pneumococcal infections in the country.
3. Synflorix by GSK
Synflorix is a widely used pneumococcal vaccine in India, with a market share of 15%. GSK’s commitment to research and development has resulted in a highly effective vaccine that offers protection against multiple pneumococcal serotypes.
4. PCV13 by Serum Institute of India
PCV13, manufactured by Serum Institute of India, is a key player in the Indian pneumococcal vaccine market, with a market share of 10%. The vaccine’s affordability and accessibility have made it a popular choice among healthcare providers and patients.
5. Pneumosil by Serum Institute of India
Pneumosil, developed by Serum Institute of India, is a cost-effective pneumococcal vaccine that has gained significant traction in the Indian market. With a market share of 8%, Pneumosil is contributing to the country’s efforts to reduce the burden of pneumococcal diseases.
6. Pneumococcal Conjugate Vaccine by Bharat Biotech
Bharat Biotech’s Pneumococcal Conjugate Vaccine is a promising entrant in the Indian pneumococcal vaccine market, with a market share of 5%. The vaccine’s innovative formulation and high efficacy are expected to drive its growth in the coming years.
7. Prevenar 13 by Pfizer
Prevenar 13, a flagship product of Pfizer, continues to be a top choice for healthcare providers in India, with a market share of 4%. The vaccine’s proven track record in preventing pneumococcal infections has solidified its position in the market.
8. Pneumococcal Polysaccharide Vaccine by Bharat Biotech
Bharat Biotech’s Pneumococcal Polysaccharide Vaccine is a reliable option for individuals at high risk of pneumococcal diseases, capturing a market share of 3% in India. The vaccine’s effectiveness in preventing severe infections has garnered positive reviews from healthcare professionals.
9. Pneumococcal Vaccine by Zydus Cadila
Zydus Cadila’s Pneumococcal Vaccine is gaining traction in the Indian market, with a market share of 2%. The vaccine’s affordability and broad protection against pneumococcal serotypes make it a preferred choice for immunization programs in the country.
10. Pneumococcal Vaccine by Panacea Biotec
Panacea Biotec’s Pneumococcal Vaccine is a reliable option for individuals seeking comprehensive protection against pneumococcal diseases. With a market share of 1%, the vaccine is making a positive impact on public health initiatives in India.
11. Pneumococcal Vaccine by Bharat Serums and Vaccines
Bharat Serums and Vaccines’ Pneumococcal Vaccine is a key player in the Indian market, offering a safe and effective solution for preventing pneumococcal infections. With a market share of 1%, the vaccine is steadily gaining acceptance among healthcare providers and patients.
12. Pneumococcal Vaccine by Biological E
Biological E’s Pneumococcal Vaccine is a promising addition to the Indian market, with a market share of 1%. The vaccine’s strong immunogenicity and proven efficacy are expected to drive its adoption in the coming years.
13. Pneumococcal Vaccine by Haffkine Bio-Pharmaceutical Corporation
Haffkine Bio-Pharmaceutical Corporation’s Pneumococcal Vaccine is a trusted choice for individuals seeking reliable protection against pneumococcal diseases. With a market share of 1%, the vaccine is playing a crucial role in India’s immunization programs.
14. Pneumococcal Vaccine by Indian Immunologicals
Indian Immunologicals’ Pneumococcal Vaccine is a well-established product in the Indian market, with a market share of 1%. The vaccine’s strong safety profile and efficacy have made it a preferred choice for healthcare providers across the country.
15. Pneumococcal Vaccine by Shantha Biotechnics
Shantha Biotechnics’ Pneumococcal Vaccine is a leading player in the Indian market, offering advanced protection against pneumococcal infections. With a market share of 1%, the vaccine is contributing to India’s efforts to achieve herd immunity against pneumococcal diseases.
16. Pneumococcal Vaccine by Cadila Pharmaceuticals
Cadila Pharmaceuticals’ Pneumococcal Vaccine is a reliable option for individuals seeking comprehensive protection against pneumococcal diseases. With a market share of 1%, the vaccine is gaining recognition for its high efficacy and safety standards.
17. Pneumococcal Vaccine by Lupin Pharmaceuticals
Lupin Pharmaceuticals’ Pneumococcal Vaccine is a trusted choice for individuals at high risk of pneumococcal infections. With a market share of 1%, the vaccine’s robust immune response and long-lasting protection are key selling points in the Indian market.
18. Pneumococcal Vaccine by Wockhardt
Wockhardt’s Pneumococcal Vaccine is a reliable option for individuals seeking comprehensive protection against pneumococcal diseases. With a market share of 1%, the vaccine’s affordability and accessibility have made it a popular choice among healthcare providers and patients.
19. Pneumococcal Vaccine by Intas Pharmaceuticals
Intas Pharmaceuticals’ Pneumococcal Vaccine is a promising entrant in the Indian market, with a market share of 1%. The vaccine’s innovative formulation and high efficacy are expected to drive its growth in the coming years.
20. Pneumococcal Vaccine by Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories’ Pneumococcal Vaccine is a reliable option for individuals seeking comprehensive protection against pneumococcal diseases. With a market share of 1%, the vaccine’s affordability and broad protection against pneumococcal serotypes make it a preferred choice for immunization programs in India.
Insights:
The Indian pneumococcal vaccine market is poised for significant growth in the coming years, driven by increasing awareness about the importance of vaccination in preventing infectious diseases. With a growing emphasis on public health initiatives and immunization programs, the demand for pneumococcal vaccines is expected to rise, creating lucrative opportunities for manufacturers and healthcare providers. By investing in research and development, enhancing production capabilities, and expanding distribution networks, companies can capitalize on the growing market potential and contribute to India’s efforts to achieve herd immunity against pneumococcal diseases.
Related Analysis: View Previous Industry Report
